CD200-expressing human basal cell carcinoma cells initiate tumor growth

Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2013-01, Vol.110 (4), p.1434-1439
Hauptverfasser:	Colmont, Chantai S., BenKetah, Antisar, Reed, Simon H., Hawk, Nga V., Telford, William G., Ohyama, Manabu, Udey, Mark C., Yee, Carole L., Vogel, Jonathan C., Patel, Girish K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals antagonists Antigens, CD - metabolism Basal cell carcinoma Basal cell neoplasms Biological Sciences Cancer Carcinoma, Basal Cell - immunology Carcinoma, Basal Cell - metabolism Carcinoma, Basal Cell - pathology Cell Differentiation Cell growth Cell Proliferation Cells drugs fluorescence microscopy Genes Hair follicles Heterologous transplantation Humans Keratins Keratins - metabolism Kruppel-Like Factor 4 Medical treatment Mice Mice, Inbred NOD Mice, Nude Mice, SCID neoplasm cells neoplasms Receptors, G-Protein-Coupled - antagonists & inhibitors Skin Neoplasms - immunology Skin Neoplasms - metabolism Skin Neoplasms - pathology Smoothened Receptor Stem cells therapeutics Tissue grafting transcription factors Transplantation, Heterologous Tumor Stem Cell Assay Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!